{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T12:22:36Z","timestamp":1780489356688,"version":"3.54.1"},"reference-count":22,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2009,1,5]],"date-time":"2009-01-05T00:00:00Z","timestamp":1231113600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Acad Dermatol Venereol"],"published-print":{"date-parts":[[2009,3]]},"abstract":"<jats:sec><jats:title>Abstract<\/jats:title><jats:p><jats:bold>Objective\u2002<\/jats:bold> To compare the efficacy and safety of intermittent terbinafine with standard courses of terbinafine and itraconazole for dermatophyte toenail onychomycosis.<\/jats:p><jats:p><jats:bold>Design\u2002<\/jats:bold> Data from a Canadian study of continuous terbinafine (CTERB) and intermittent itraconazole (III) was compared to an intermittent terbinafine regimen (TOT) using similar protocol to the randomized study.<\/jats:p><jats:p><jats:bold>Interventions\u2002<\/jats:bold> Terbinafine 250\u00a0mg\/day for 4\u00a0weeks followed by 4\u00a0weeks of no terbinafine and then an additional 4\u00a0weeks of terbinafine 250\u00a0mg\/day (TOT); terbinafine 250\u00a0mg\/day for 12\u00a0weeks (CTERB); itraconazole pulse of 200\u00a0mg twice daily for 7\u00a0days on, 21\u00a0days off, three pulses given (III).<\/jats:p><jats:p><jats:bold>Results\u2002<\/jats:bold> At 72\u00a0weeks, mycological cure rates (negative KOH and culture) were 36 of 43 (83.7%), 25 of 32 (78.1%), and 17 of 30 (56.7%), for the TOT, CTERB, and III groups, respectively (<jats:italic>P\u00a0=<\/jats:italic>\u00a00.01 for TOT vs. III). Effective cure rates (simultaneous mycological cure and\u00a0\u226410% nail plate involvement) were 34 of 43 (79.1%), 21 of 32 (65.6%), and 11 of 30 (36.7%), respectively (<jats:italic>P\u00a0&lt;<\/jats:italic>\u00a00.001 for TOT vs. III; <jats:italic>P\u00a0=<\/jats:italic>\u00a00.02 for CTERB vs. III). No significant differences in effective and mycological cure rates were noted between the two terbinafine groups. Adverse events reported were similar to those reported in the respective package inserts. Most adverse events were mild to moderate, transient, and did not require interruption of the drug regimens. No serious adverse events were reported.<\/jats:p><jats:p><jats:bold>Conclusions\u2002<\/jats:bold> A TOT intermittent terbinafine regimen provided similar efficacy and safety to the gold standard continuous terbinafine regimen and better effective cure rates than pulse itraconazole therapy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conflicts of interest<\/jats:title><jats:p>None declared<\/jats:p><\/jats:sec>","DOI":"10.1111\/j.1468-3083.2008.03036.x","type":"journal-article","created":{"date-parts":[[2009,1,5]],"date-time":"2009-01-05T23:09:19Z","timestamp":1231196959000},"page":"256-262","source":"Crossref","is-referenced-by-count":50,"title":["The use of an intermittent terbinafine regimen for the treatment of dermatophyte toenail onychomycosis"],"prefix":"10.1111","volume":"23","author":[{"given":"AK","family":"Gupta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"LE","family":"Lynch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N","family":"Kogan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"EA","family":"Cooper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2009,2,9]]},"reference":[{"key":"e_1_2_5_2_2","doi-asserted-by":"publisher","DOI":"10.1067\/mjd.2000.104794"},{"key":"e_1_2_5_3_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.318.7190.1031"},{"key":"e_1_2_5_4_2","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.138.3.353"},{"key":"e_1_2_5_5_2","unstructured":"Lamisil (terbinafine hydrochloride tablets) Package insert.Novartis Pharmaceuticals Corporation East Hanover NJ 2004."},{"key":"e_1_2_5_6_2","doi-asserted-by":"crossref","first-page":"305","DOI":"10.2340\/000155557300304","article-title":"Levels of terbinafine in plasma, stratum corneum, dermis\u2010epidermis (without stratum corneum), sebum, hair and nails during and after 250\u00a0mg terbinafine orally once per day for four weeks","volume":"73","author":"Faergemann J","year":"1993","journal-title":"Acta Derm Venereol"},{"key":"e_1_2_5_7_2","doi-asserted-by":"publisher","DOI":"10.1080\/09546630252775171"},{"key":"e_1_2_5_8_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.1999.02614.x"},{"key":"e_1_2_5_9_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.2002.04639.x"},{"key":"e_1_2_5_10_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1346-8138.1996.tb04009.x"},{"key":"e_1_2_5_11_2","doi-asserted-by":"publisher","DOI":"10.1067\/mjd.2001.110644"},{"key":"e_1_2_5_12_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1468-3083.2002.00487_12.x"},{"key":"e_1_2_5_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0190-9622(96)80057-0"},{"key":"e_1_2_5_14_2","first-page":"1253","article-title":"Intermittent terbinafine for toenail onychomycosis: is it effective? Results of a randomized pilot trial","volume":"137","author":"Warshaw EM","year":"2001","journal-title":"Arch Dermatol"},{"key":"e_1_2_5_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0733-8635(03)00026-3"},{"key":"e_1_2_5_16_2","doi-asserted-by":"publisher","DOI":"10.1080\/13693780701549364"},{"key":"e_1_2_5_17_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1439-0507.2007.01325.x"},{"key":"e_1_2_5_18_2","doi-asserted-by":"publisher","DOI":"10.1099\/jmm.0.46542-0"},{"key":"e_1_2_5_19_2","doi-asserted-by":"publisher","DOI":"10.1080\/09546630410018076"},{"key":"e_1_2_5_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(92)90595-T"},{"key":"e_1_2_5_21_2","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.136.7.940"},{"key":"e_1_2_5_22_2","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.140.6.691"},{"key":"e_1_2_5_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2005.04.055"}],"container-title":["Journal of the European Academy of Dermatology and Venereology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1468-3083.2008.03036.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1468-3083.2008.03036.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,10]],"date-time":"2023-10-10T12:58:12Z","timestamp":1696942692000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1468-3083.2008.03036.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,2,9]]},"references-count":22,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2009,3]]}},"alternative-id":["10.1111\/j.1468-3083.2008.03036.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1468-3083.2008.03036.x","archive":["Portico"],"relation":{},"ISSN":["0926-9959","1468-3083"],"issn-type":[{"value":"0926-9959","type":"print"},{"value":"1468-3083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,2,9]]}}}